iqvia host investor day new york tuesday june come month
compani last investor day three year im quintil first announc
agreement combin overal messag manag upbeat updat
long-term financi target reflect higher organ revenu growth across three
segment convict level increas notabl combin data legaci
im clinic expertis quintil produc effici gain client
competit advantag iqvia compani appear gain momentum
technolog side busi nice progress sell commerci suit oce
plan roll-out later year clinic suit oct
make modest chang model reflect manag outlook
next three year chang target guidanc
maintain increas adjust ep target
reiter outperform rate stock view best posit present
among pharma outsourc group given acceler growth servic side
busi greater recognit technolog side gain market share well
stock trade two-turn premium cro group view premium
sustain upsid potenti technolog roll-out
twenti differ member manag present investor day although
messag firmli control ceo bousbib perspect messag
sum mission accomplish quintiles/im merger
low hang fruit deal cost synergi larg realiz advantag
link big data quintil deliveri engin sustain biopharma
industri embrac data analyt machin learn play right strength
iqvia impress quickli compani turn concept
return equiti ttm
iqvia integr inform technology-en healthcar servic provid annual revenu
base billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
macro commentari biopharma industri favor unchang innov see rise cost
requir bring new product market yet price flexibl new drug constrain payer
increasingli demand real world evid drug valu addit bulk drug discoveri continu
shift emerg compani account estim two-third industri pipelin manag
quot cro market growth rate note metric slow past year two
estim consist heard other late icon iclr outperform manag
quot market growth growth stock confer two week ago
note manag emerg biopharma sponsor becom larger driver demand industri
result fund trend key metric watch see exhibit technolog provid serv
small biotech effect best posit gain share would normal posit iqviath
largest cro fargiven larger tend better serv larg pharma smaller tend better serv small
biotech intrigu hear richard staub presid iqvia describ recent launch
dedic biotech busi unit good success note serv emerg biotech
compani ad past year
exhibit total biotech industri fund present
data remain integr long-term thesi iqvia continu emphas import data long-term
growth plan technolog segment new convict behind
strategi increas significantli natalia kotchi vice presid appli data scienc center
solut provid impress array statist indic data engin work make cro
effici trial run use data engin span site patient note
across repres studi site identif time declin non-enrol site declin
patient recruit rate improv manag found data engin improv
protocol present client
 solut gain steam given compel evid data improv clinic trial effici
believ iqvia abl continu gain share given broadest data asset industri
million de-identifi individu across countri believ grow recognit also benefit
outperform earli pioneer conceptand expect larg clinic
seek emul strategi iqvia expect segment grow organ
overal next three year nice step prior midsingle-digit growth target
importantli believ iqvia perhap best posit among use technolog machin
learn autom histor labor-intens busi highlight improv model
central monitor patient portal enabl virtual trialstwo major pain point clinic trial
discuss contract sale virtual discuss compani smallest segment
manag busi present contract sale busi clearli view manag
y/i sequenti william blair
strateg appear set return growth end year manag note three-year object
busi growth larg improv steadi declin sinc merger
modest balanc sheet de-lever expect pleas hear cfo mike mcdonnel indic goal
lower compani net leverag ratio slightli time ebitda prior target rang
time leverag balanc sheet concern investor believ businesss cash flow
natur delev time ebitda next year potenti also pay debt pace
technolog commentari encourag technolog analyt solut ta segment histor grown
organ pace pick last two quarter manag expect
busi grow organ next three year commerci suit oce begin ramp
client clinic suit oct set roll end year manag show number
client testimoni oce platform note win sinc decemb launch includ two among
top pharma client see nice opportun iqvia grab share clinic technolog segment
particularli recent announc purchas medidata mdso market perform see
driver potenti valuat upsid well
maintain estim increas revenu target million million
due higher organ growth target billion increas ebitda target
million billion increas ep target estim ep growth
next year inclus buyback compar previous exhibit
valuat stock thought
tuesday close share trade time unchang ep estim two turn
clinic cro group averag multipl time despit rel premium maintain
outperform rate iqvia given increasingli clear sign share gain encourag commentari
manag analyst day
view follow key risk iqvia next three five year slowdown spend
environ due lower end-market price exogen factor materi reduct amount
biotech fund increas competit price pressur clinic cro industri
gener administr amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross profit beg beg rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
